We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Turalio

News List

Daiichi Sankyo secures FDA approval for Turalio to treat TGCT patients pharmaceutical-technology
August 06, 2019
Daiichi Sankyo has secured the US Food and Drug Administration (FDA) approval for its Turalio (pexidartinib) capsules to treat adult patients with symptomatic tenosynovial giant cell tumour (TGCT).
Turalio (Pexidartinib) Approved to Treat Tenosynovial Giant Cell Tumor drugs
August 06, 2019
Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT)...
FDA approves Daiichi Sankyo's TURALIO biospectrumasia
August 05, 2019
TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults drugs
August 05, 2019
The U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with...